Men's Health News

RSS

Researchers develop PHI test to help determine aggressiveness of prostate cancer

Researchers at Johns Hopkins University have developed what could be a promising new test to help determine the aggressiveness of prostate cancer, says a Bay Area urologist who specializes in treating the disease, although patients may not realize any benefits for another decade or longer.

19 May 2010

New multi-center follow-up study of NX-1207 for treatment of BPH to be completed

Nymox Pharmaceutical Corporation announced today that the Company is nearing completion of a new multi-center U.S. long-term follow-up study of NX-1207, its investigational drug for the treatment of benign prostatic hyperplasia.

19 May 2010

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Generex Biotechnology Corporation announced today publication of results from the first Phase I study of its lead immunotherapeutic agent AE37 in patients with prostate cancer. At the end of 2009, the Company announced positive interim results from a Phase II trial being conducted with AE37 in patients with breast cancer. The compound is being developed by its wholly-owned subsidiary, Antigen Express, Inc.

19 May 2010

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Harbor BioSciences, Inc. today announced that new data from the Phase I/IIa clinical trial of the company's lead drug candidate Apoptone®, its anticancer drug candidate being developed for prostate cancer, will be presented as part of the Scientific Program in a General Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.

18 May 2010

Study reviews impact of focal therapy for low-risk prostate cancer patients

In the July issue of European Urology, the scientific journal of the European Association of Urology, the significance and impact of focal therapy for low-risk cancer patients is discussed in a recent study by S. Eggener et al.

18 May 2010

New DVS radiation measurement device for prostate cancer treatment

John Theurer Cancer Center at Hackensack University Medical Center announced today that it is one of two cancer centers in the tri-state area currently implanting a wireless radiation sensor, known as DVS. John Theurer Cancer Center radiation oncologists can now receive data immediately post- treatment on the precise amount of radiation being delivered to tumors and surrounding tissue for prostate cancer treatments.

18 May 2010

Low testosterone levels can impact sleep quality

At 30 years old, male testosterone levels drop by one to two percent annually. By age 40, men's quality of sleep begins to diminish. Could there be a link between decreased testosterone and reduced sleep?

15 May 2010

Rich Canadian men increase their likelihood of being overweight

In Canada, in stark contrast with the rest of the world, wealthy men increase their likelihood of being overweight with every extra dollar they make. The new study was led by Nathalie Dumas, a graduate student at the University of Montreal Department of Sociology, and presented at the annual conference of the Association francophone pour le savoir.

15 May 2010

Multivitamin and mineral supplements improve mood, mental performance in healthy males: Study

The effects of multivitamins are most often researched in the elderly. This is one of very few studies to assess the relationship between supplementation with vitamins/minerals and psychological functioning in healthy groups of non-elderly adults. This study shows how a proprietary multivitamin and mineral supplement improves mood and mental performance while also reducing stress, mental tiredness and fatigue in healthy males.

14 May 2010

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

Castration-resistant prostate cancer (CRPC), defined as tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Current treatment regimens are complicated by toxicities and a low rate of relapse-free survival. Many novel therapies in clinical trials offer hope for patients with this challenging diagnosis. Healthcare professionals who are treating CRPC must stay abreast of these emerging therapies to ensure optimal care for these patients.

14 May 2010

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will initiate a Phase IIb clinical trial for ZoraxelTM in the treatment of erectile dysfunction (ED).

13 May 2010

25% of adults quit their overactive bladder medication: Study

Study of 5,392 adults found that a quarter had quit their overactive bladder medication, with nine out of ten saying it didn't work as expected or they couldn't tolerate it. A follow-up study found that being a current smoker raised the risk of quitting by 80%, having an enlarged prostate by 74% and believing that bladder medication caused side effects by 111%.

13 May 2010

Researchers develop new technology to manage prostate cancer treatment

Researchers at Queen's University have developed a new way of performing lab tests that could improve the way doctors manage prostate cancer treatment. It will allow them to identify with unprecedented accuracy losses of a gene called PTEN that is associated with an aggressive group of prostate cancers.

13 May 2010

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date.

12 May 2010

Allergic conditions that result from hyper reactive immune system may lower cancer risk: Study

If you have asthma or eczema, your hyper reactive immune system may lower your risk of some of the most common types of cancer, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology.

12 May 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

Older Americans staying sexually active but not practicing safe sex

Sexual activity continues to thrive with the 45+ demographic according to a new AARP sex survey, Sex, Romance, and Relationships: AARP Survey of Midlife and Older Adults, released today. However, older adults are not necessarily practicing what they preach to younger generations, with results showing a low use of protection among sexually active dating singles with only one in five reporting use of condoms regularly.

11 May 2010

UNC-CH awarded $100,000 Grand Challenges Explorations grant for study of ultrasound as a contraceptive

The University of North Carolina at Chapel Hill has received a $100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by James Tsuruta, PhD, and Paul Dayton, PhD, titled "Ultrasound as a long-term, reversible contraceptive."

11 May 2010

Medical options to help prostate cancer patients make informed treatment decisions

While the dreaded words "You have prostate cancer" often leave patients confused, the impact of the diagnosis can extend to the entire family, especially wives, says a top expert.

10 May 2010

Experts to present latest research on prostate cancer and related conditions

WHAT: This symposium features a renowned faculty of clinicians and researchers who will present leading-edge information on the best standards of care in managing the full spectrum of prostate cancer and related conditions.

10 May 2010

Men's Health News

Researchers develop PHI test to help determine aggressiveness of prostate cancer

New multi-center follow-up study of NX-1207 for treatment of BPH to be completed

Generex Biotechnology's Phase I study data of AE37 for prostate cancer published

Harbor BioSciences announces presentation of new data from Apoptone Phase I/IIa trial at ASCO Annual Meeting

Study reviews impact of focal therapy for low-risk prostate cancer patients

New DVS radiation measurement device for prostate cancer treatment

Low testosterone levels can impact sleep quality

Rich Canadian men increase their likelihood of being overweight

Multivitamin and mineral supplements improve mood, mental performance in healthy males: Study

RMEI, PIM sponsor continuing education series on castration-resistant prostate cancer

Rexahn Pharmaceuticals announces Phase IIb clinical trial of Zoraxel for ED

25% of adults quit their overactive bladder medication: Study

Researchers develop new technology to manage prostate cancer treatment

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Allergic conditions that result from hyper reactive immune system may lower cancer risk: Study

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Older Americans staying sexually active but not practicing safe sex

UNC-CH awarded $100,000 Grand Challenges Explorations grant for study of ultrasound as a contraceptive

Medical options to help prostate cancer patients make informed treatment decisions

Experts to present latest research on prostate cancer and related conditions

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News